Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration

The purpose of this study is to compare 12-month results of two single initial treatments-photodynamic therapy with verteporfin alone and this therapy combined with intravitreal bevacizumab-for neovascular age-related macular degeneration, not including patients with polypoidal choroidal vasculopathy who were presumed to have age-related macular degeneration.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age-Related Macular Degeneration Eye Diseases Macular Degeneration Retinal Degeneration Retinal Diseases

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Ophthalmology and Visual Science, Graduate School of Medical Sciences, Kumamoto University

Kumamoto, 860-8556, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

choroidal neovascularization caused by age-related macula degeneration
no previous treatment
a follow-up at least 12 months
a baseline visual acuity ranging from a letter score of 0 to 70 on the Early Treatment Diabetic Retinopathy Study chart

Exclusion criteria

choroidal neovascularization caused by other eye diseases
ocular surgery within the past 3 mouths
history of uveitis
intraocular pressure higher than 25 mmHg, or glaucoma
history of systemic or ocular thromboembolic events.

Treatment and study plan

Bevacizumab

Drug

A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.

Other names: Avastin

Primary outcomes

Visual acuity

Time frame: The comparison between baseline and 12-month

Sponsors and collaborators

Lead sponsor

Kumamoto University

Other

Registry information

Official study title

Verteporfin Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Neovascular Age-related Macular Degeneration

Important dates

Study start: 2006
Primary completion: 2008
Study completion: 2008
First posted: Dec 15, 2009
Registry last updated: Feb 26, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed